New contraceptive method using KLK3 inhibitors to prevent pregnancy
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-11228560
This study is exploring a new way to prevent pregnancy by using a special approach that keeps semen from changing to a watery state, which helps sperm move; it's designed for women who want a non-hormonal and reversible option for birth control.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-11228560 on ClinicalTrials.gov |
What this research studies
This research investigates a novel contraceptive approach that targets the liquefaction of semen to prevent sperm from reaching the egg. By using specific inhibitors of the enzyme KLK3, the study aims to block the transition of semen from a gel-like state to a watery consistency, which is crucial for sperm motility. This method is designed to be non-hormonal and fully reversible, providing an alternative for women who prefer not to use hormonal contraceptives. The research builds on previous findings that demonstrated the effectiveness of serine protease inhibitors in preventing pregnancy in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are women of reproductive age, especially those seeking non-hormonal contraceptive options.
Not a fit: Patients who are not seeking contraception or those who are already using effective hormonal contraceptive methods may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective, and non-hormonal contraceptive option for women, particularly benefiting those who have had difficulty with existing methods.
How similar studies have performed: While hormonal contraceptives are well-established, this approach using KLK3 inhibitors is novel and has not been widely tested in human subjects.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WINUTHAYANON, WIPAWEE — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: WINUTHAYANON, WIPAWEE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.